GlassScriptPhysician profile
Mark M Anderson
NPI 1538132170
$3,959.77
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $688 · 2021: $899 · 2022: $838 · 2023: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $848.21 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $820.23 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $744.22 | 2019-2023 | |
| Abbvie INC. | $657.25 | 2019-2023 | Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $430.49 | 2019-2023 | Entyvio |
| Celgene Corporation | $170.55 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $91.00 | 2019 | |
| Merck Sharp & Dohme LLC | $49.32 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $41.29 | 2019 | |
| Evoke Pharma, INC. | $30.03 | 2021 | |
| Concordia Pharmaceuticals INC. | $27.70 | 2019 | |
| Braintree Laboratories, INC. | $26.56 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.61 | 2020 | |
| Allergan, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.